CONMED CORPORATION— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$373M
↑+7.9% +$27Mvs FY2024 (Q4)
Gross Profit
$218M
↑+10.1% +$20Mvs FY2024 (Q4)
Operating Income
$37M
↓-30.2% -$16Mvs FY2024 (Q4)
Net Income
$17M
↓-50.4% -$17Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $373M | $346M |
| COGS | $155M | $148M |
| Gross Profit | $218M | $198M |
| R&D | $15M | $13M |
| SG&A | $167M | $133M |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $37M | $52M |
| Interest Exp. | $7M | $9M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $29M | $44M |
| Tax | $13M | $10M |
| Net Income | $17M | $34M |
QuarterCharts · SEC EDGAR data · CNMD · Comparing FY2025 (Q4) vs FY2024 (Q4)